Members of Congress recently reintroduced bipartisan legislation, the CLINICAL TREATMENT Act (H.R. 913), which would guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition. ASCO worked closely with the bill’s sponsors, Representatives Ben Ray Lujan (D-NM-03) and Gus Bilirakis (R-FL-12), to shape the legislation to address a significant barrier to participation in clinical trials. The society also led a community endorsement letter that 86 organizations signed, thanking the sponsors for their leadership on this issue and urging Congress to advance the legislation.
Passing the CLINICAL TREATMENT Act would:
- Improve quality of cancer research: Medicaid insures a large portion of people from under-represented minority and ethnic groups who are not well represented in clinical trial enrollment. Lack of participation in clinical trials from the Medicaid population means these patients are not reflected in the outcome of the clinical research. Improving the representation of this group would improve the validity of clinical research data and the quality of new treatments.
- Reduce disparities in cancer care: Clinical trials often provide people with cancer with their best clinical option. Covering routine costs of clinical trials for patients with Medicaid coverage could help to reduce health disparities and ensure access to the high-quality, high-value cancer care.
- Cover only routine costs of care: Providing coverage for the routine costs of clinical trials would have a minimal effect on overall care costs. In most cases, these costs consist of coverage for care that patients would be receiving anyway. The cost of the investigational device or drug would still be covered by the trial sponsor.
Nearly 20 percent of Americans receive their health insurance coverage through Medicaid. However, unlike Medicare and private and commercial payers, Medicaid is not federally required to cover routine care costs (like physician visits and laboratory studies) for clinical trials.
Read the community endorsement letter signed by 86 organizations.
Bookmark ASCO in Action for the latest cancer policy news and information